iDCL / DCLP3
2019
Six-Month Randomised Trial of a Closed-Loop System in Type 1 Diabetes
In 168 patients aged 14–71 with type 1 diabetes, hybrid closed-loop insulin delivery (Control-IQ) improved time-in-range and HbA1c compared with sensor-augmented pump therapy.
Result
- Absolute difference
- 12 points
- NNT
- 9
difference (pp)11P < 0.001
Absolute difference and NNT are derived from the event rates.
Also reported: HbA1c difference −0.3 %; no severe hypoglycaemia.
- Subtopic
- Hybrid closed-loop insulin
- Design
- Open-label RCT, 6 mo
- Relevance
- Supporting: context rather than must-know.
- Source
- Brown SA, et al. N Engl J Med. 2019;381(18):1707-1717.doi 10.1056/NEJMoa1907863
Discussion & critique
Basis of the FDA clearance of Control-IQ. Hybrid closed-loop systems are now standard of care for T1DM in many countries.